GlassScriptPhysician profile
Wee J Jung
NPI 1194790634
$4,478.38
in general payments reported to CMS, 2019-2025
18 companies · $897 in 2025
The $897 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $359 · 2021: $347 · 2022: $525 · 2023: $768 · 2024: $1,114 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,509.02 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $633.16 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $455.87 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $381.87 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $263.96 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $223.39 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $182.34 | 2021-2025 | |
| Neos Therapeutics, LP | $179.51 | 2019-2022 | |
| Pfizer INC. | $144.21 | 2019-2024 | |
| Adlon Therapeutics L.P. | $113.38 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $90.59 | 2025 | Neffy |
| Arbor Pharmaceuticals, INC. | $87.88 | 2019-2020 | |
| Seqirus USA INC | $71.21 | 2024 | Flucelvax |
| Merck Sharp & Dohme LLC | $62.25 | 2019-2023 | Rotateq, M-M-R II, Gardasil 9 |
| Ortho-Clinical Diagnostics, INC. | $31.56 | 2024 | Sofia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $18.42 | 2023 | |
| Cranial Technologies, INC | $17.50 | 2025 | Doc Band |
| Glaxosmithkline, LLC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wee Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.